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Objective. Quantitatively summarize patient preferences for European licensed relapsing-remitting multiple sclerosis
(RRMS) disease-modifying treatment (DMT) options. Methods. To identify and summarize the most important
RRMS DMT characteristics, a literature review, exploratory physician interviews, patient focus groups, and confir-
matory physician interviews were conducted in Germany, the United Kingdom, and the Netherlands. A discrete
choice experiment (DCE) was developed and executed to measure patient preferences for the most important DMT
characteristics. The resulting DCE data (n=799 and n=363 respondents in the United Kingdom and Germany,
respectively) were analyzed using Bayesian mixed logit models. The estimated individual-level patient preferences
were subsequently summarized using 3 additional analyses: the quality of the choice data was assessed using
individual-level R2 estimates, individual-level preferences for the available DMTs were aggregated into DMT-specific
preference shares, and a principal component analysis was performed to explain the patients’ choice process. Results.
DMT usage differed between RRMS patients in Germany and the United Kingdom but aggregate patient prefer-
ences were similar. Across countries, 42% of all patients preferred oral medications, 38% infusions, 16% injections,
and 4% no DMT. The most often preferred DMT was natalizumab (26%) and oral DMT cladribine tablets (22%).
The least often preferred were mitoxantrone and the beta-interferon injections (1%–3%). Patient preferences were
strongly correlated with patients’ MS disease duration and DMT experience, and differences in patient preferences
could be summarized using 8 principle components that together explain 99% of the variation in patients’ DMT pre-
ferences. Conclusion. This study summarizes patient preferences for the included DMTs, facilitates shared decision
making along the dimensions that are relevant to RRMS patients, and introduces methods in the medical DCE litera-
ture that are ideally suited to summarize the impact of DMT introductions in preexisting treatment landscapes.
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Multiple sclerosis (MS) is a chronic demyelinating dis-
ease of the central nervous system characterized by
inflammation and axonal degeneration.1 Approximately
85% of all patients are initially diagnosed with relapsing-
remitting MS (RRMS), which is characterized by
exacerbations and periods of disease stability after recov-
ery.2 Disease-modifying treatments (DMTs) that target
immunological signaling proteins (e.g., interferons and
cytokines) or populations of immune cells (e.g., lympho-
cytes) are typically used to treat RRMS.3 DMTs are rela-
tively successful in controlling inflammatory activity
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(i.e., relapses); however, they only reduce the rate of pro-
gression of neurodegenerative processes and do not cure
the disease.3,4
Because no optimal DMT for RRMS exists, therapy
should be tailored to individual patient preferences as
well as disease progression.5 Patient preferences are even
referred to as ‘‘critical’’ in recently published American
Academy of Neurology practice guideline recommenda-
tions.6 Consequently, there is an intrinsic need for MS
patient preference studies in the field of clinical neurol-
ogy, that is, beyond the general need for patient-centered
care that is respectful of and responsive to individual pre-
ferences in clinical decisions.7,8 Appendix A in the
Supplementary Material provides a structured overview
of previously published MS patient preference studies.9–23
This research has been informative regarding the general
stance of MS patients on risk/benefit tradeoffs when
choosing between DMTs. However, these studies have
neglected one very important aspect, which is the analysis
of patient preferences for actually available treatment
profiles. Hence, although academically interesting, previ-
ous preference research has provided limited applicable
guidance to clinicians who aim to align treatment selec-
tions with patient preferences.
The goal of the current article is to complement exist-
ing MS preference research by assessing patient prefer-
ences for entire DMT profiles. Our approach is based on
discrete choice experiment (DCE) methods that are com-
monly used in the marketing literature and that can pro-
vide insight into patients’ considerations when choosing
between actual DMTs as well as aggregate information
on patient preferences for different types of DMTs.
Furthermore, the implemented approach facilitates an
evaluation of the impact of the introduction of new
DMTs, such as the recently approved cladribine tablets,
into the competitive landscape of existing treatment
options.24 Unfortunately, the most recently introduced
RRMS DMT (i.e., ocrelizumab) was not included in the
competitive landscape because sufficiently detailed infor-
mation about the side effects were unavailable during the
design of the study. However, since the presented metho-
dology is very general, new DMTs (including ocrelizu-
mab) can easily be introduced in future extensions of the
competitive landscape.
Methods
This study used a mixed methods approach. Initially,
qualitative research methods (i.e., a literature review,
exploratory physician interviews, patient focus groups,
and confirmatory physician interviews) were used to
identify and summarize the important aspects of cur-
rently licensed RRMS DMTs. Subsequently, a DCE was
developed and executed to measure patient preferences
for all relevant DMT characteristics and to quantita-
tively summarize the patient choice process.
Theoretical Foundation
In a DCE, the preference for a medical intervention, such
as an MS treatment, is established by decomposing it
into separate characteristics (referred to as ‘‘attributes’’)
and different variants of these characteristics (referred to
as ‘‘levels’’).25,26 For example, the attribute ‘‘mode of
administration’’ comprises the levels ‘‘injection,’’ ‘‘oral,’’
and ‘‘infusion.’’ The basic assumption in a DCE is that
all interventions are a combination of levels and that
individuals’ preferences for interventions can be deter-
mined based on the combined evaluation of these lev-
els.27 The relative importance of the selected levels is
empirically established by asking respondents to make
tradeoffs in a series of choice tasks. Within each choice
task, there are 2 or more interventions to choose from,
and respondents are repeatedly asked to indicate the
option that they prefer. Statistical regressions are subse-
quently used to derive numerical values for the relative
attractiveness of all attributes and levels, using methods
that have a solid foundation in random utility theory.28
Selection of Attributes and Levels and Summary
Descriptions of the DMTs
To identify the relevant attributes and levels of the
included RRMS DMTs, a literature review, exploratory
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physician interviews (n=8), and patient focus groups
(n=33 patients) were conducted in the Netherlands,
Germany, and the United Kingdom. The selection of
attributes and levels was based on a bottom-up approach
in which a so-called ‘‘competitive landscape’’ of treat-
ment options was constructed. This competitive land-
scape covered the most important dimensions of MS
treatments (i.e., administration, efficacy, side effects, and
pregnancy-related considerations). Within each dimen-
sion, a set of key attributes and levels was identified from
the literature as well as patient focus groups and physi-
cian interviews. Moreover, once the initial competitive
landscape had been constructed, several confirmatory
sessions with physicians (n=8, of which n=4 were not
included before) were conducted to verify the selection
of attributes and levels, assess the balance and accuracy
of the DMT’s descriptions, and decide on the optimal
classification of the included side effects. The interviews
were conducted in June 2016 (Germany) and September
2016 (United Kingdom).
During these confirmatory meetings, several impor-
tant decisions were made. Most importantly, side effects
were classified based on their reversibility and timing of
occurrence. This resulted in 3 categories: 1) immediately
occurring and reversible side effects, 2) reversible side
effects, and 3) irreversible side effects. In addition, it was
decided to include an attribute that described the
required screening intervals for potentially severe side
effects, such as heart failure, liver problems, leucopenia,
and macular edema. For these side effects, effective mon-
itoring generally prevents the occurrence of irreversible
side effects, although patients may be required to switch
DMTs when problems are detected.
In addition to their classification, all included side
effects were further described with an incidence descrip-
tion. For clarity and comparability, a limited set of inci-
dence categories with a common denominator of 100
was used for all frequently occurring reversible side
effects; that is, ‘‘sometimes’’ denoted approximately 10
of 100 patients, ‘‘often’’ denoted approximately 20 of 100
patients, and so forth. Similarly, a small number of inci-
dence categories with a common numerator of 1 were
used for the severe and irreversible side effects (e.g., a
‘‘very small risk’’ of approximately 1 of 30 000 patients
or a ‘‘small risk’’ of approximately 1 of 10 000 patients.
Although mixing risk communication strategies is gener-
ally not recommended, it was the preferred option to
deal with the scale incompatibility between regularly
occurring yet benign side effects versus infrequently
occurring but potentially lethal adverse events. The
clarity of the incidence descriptions was carefully tested
in think-aloud interviews.
Considerable efforts were made to accurately describe
the efficacy levels of the DMTs. Based on the literature
review, almost as many formulations of the efficacy lev-
els as DCE publications were identified. These different
formulations were included and discussed in the patient
focus groups and physician interviews. The consensus
was that absolute descriptions (e.g., treatments resulting
in exactly 2 or 3 relapses in the next 2 years) were easiest
to understand for patients. However, such absolute
descriptions were also deemed unrealistically simple and
inaccurate from a clinical perspective. Accordingly, a
relative formulation was used similar to the one used by
Wicks and colleagues,12 in which the efficacy of treat-
ments is described as being effective, quite effective, very
effective, or highly effective, which corresponds to 33%,
44%, 55%, and 66% reduction in relapse or disability
risk compared with using no MS medication at all.
In terms of disease progression, most physicians did
not explicitly differentiate between the reduction in the
number of relapses and disability progressions in their
communication with patients. The consensus was that
both aspects are intrinsically linked for all currently
available DMTs, meaning that in clinical decisions, no
tradeoffs between both aspects of efficacy are required.
In other words, if one treatment is more effective than
another in terms of reducing the number of relapses, it is
also equally or more effective in terms of reducing dis-
ability risk. An overview of the included DMTs, as well
as a description of all important considerations consti-
tuting the final selection of attributes and levels assigned
to each of the DMTs, is included in Supplementary
Appendix B.
Structure and Visual Presentation of the Choice
Tasks
In the choice tasks, combinations of the attributes and
levels that were relevant for each mode of administration
were used to construct realistic discrete choice tradeoffs.
To mitigate the cognitive burden of the survey instru-
ment, the choice tasks were separated into 4 separate
sections: 1) injections, 2) infusions, 3) oral medications,
and 4) an ‘‘overarching’’ DCE in which respondents
compared all treatment types simultaneously (see
Supplementary Appendix C). The fourth section was
used to refine the initial preference measurements and
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place them on a common utility scale. This allowed for a
direct comparison of patient preferences for all DMTs
without requiring choice tasks that simultaneously
included all of the 16 attributes in the DCE.
To further reduce the cognitive burden of the survey
(and restrict the layout of the choice tasks), the maxi-
mum number of side effects in the profiles was con-
strained to 5. In the choice tasks with equal modes of
administration, only 3 attribute levels were allowed to be
different. The differences between the choice options
were highlighted, making choice tasks substantially easier
for respondents.29,30 In addition, the format of the side
effects was programmed to show only the side effects
that were relevant for each treatment option, instead of
also showing potential adverse effects that were not asso-
ciated with a particular treatment option. This again
reduced the complexity of the choice tasks and was con-
sidered more realistic and congruent with how physicians
describe differences between treatment options to their
patients.
Carefully constructed warm-up tasks were used to
gradually explain all relevant attributes and levels in the
DCE. Alternating information screens and warm-up
tasks were used to first introduce 1 or 2 related attributes
(e.g., using a figure and/or a few sentences), followed by
a choice task to clarify the tradeoff involved (see Figure
2). During the warm-up tasks, the complexity of the
visual presentation was gradually increased by always
including previously explained treatment attributes in the
layout. This way, by the end of the warm-up questions,
all respondents were fully accustomed to the choice for-
mat used in the regular DCE questions.
DCE Design
To create an efficient DCE design that adhered to the
level overlap constraints and included only realistic treat-
ment options with side effects and efficacies that are rele-
vant for each mode of administration, a custom
optimization algorithm had to be developed. This algo-
rithm was based on the methods introduced by Sa´ndor
and Wedel31 and was implemented in the Fortran pro-
gramming language. The algorithm created 10 different
versions of the DCE design, each comprising 15 fixed
warm-up tasks and 28 (i.e., 4 3 7) regular discrete
choice tasks, with DCE sample size calculations as
described by de Bekker-Grob and colleagues32 used to
ensure adequate statistical power. During the data col-
lection, the DCE design was improved several times to
better reflect previously observed patient preferences and
increase statistical efficiency.
Survey Development and Patient Recruitment
After the development of an initial version of the DCE
design, the survey was piloted in Germany. In total, 3
German pilot studies were held with a total of 112
RRMS patients aged 18 years and older recruited via
Neurotransdata. The recruitment source implied that
patients were invited by their treating physicians to par-
ticipate in the survey. Patients completed the question-
naire in their own clinic and under supervision of their
own MS nurse. The MS nurses also actively helped to
improve the survey instrument until it was considered
suitable for unattended administration to MS patients.
At this point, the German survey was translated into
English and piloted in an online sample of 164 respon-
dents from the United Kingdom recruited via Opinion
Health. Based on the patient satisfaction scores, cogni-
tive debriefing questions, and DCE sample size calcula-
tions, no further changes to the survey structure were
required. This allowed for the UK data collection to be
completed and the initiation of the online component of
the German data collection, which was conducted by
Survey Sampling International alongside continued data
collection via Neurotransdata. All data were collected
from January to June 2017.
Survey Satisfaction and Verification
of the Choice Data
After the data collection, the included survey satisfaction
and cognitive debriefing questions were summarized by
averaging their 7-point Likert-type scores. The survey’s
dropout rates were directly observed, and completion tim-
ings were calculated as the cumulative time spent on the
pages of the questionnaire, maximized at 10 minutes per
page to correct for respondents taking a break in between
survey questions. Finally, individual-level R2 statistics (see
the next section) were calculated to assess the quality of the
choice data and identify respondents with illogical response
structures.
Econometric Analyses
Bayesian methods were used to estimate population and
individual-level patient preferences for the German and
UK samples using mixed logit (MIXL) models.33 Such
models use the observed choices as the dependent vari-
able and the characteristics of the choice options as
explanatory variables. The estimations were conducted
using OpenBUGS and based on a run of 200 000 Markov
Chain Monte Carlo (MCMC) draws, with the initial
100 000 discarded as burn-in iterations. Convergence was
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Figure 1 Example disease-modifying treatments (DMTs). The actual DMTs were not included in the survey and were not shown
to respondents. Please see Supplementary Appendix B for a description of all DMTs in terms of the selected attributes and levels.
*Only relevant for John Cunningham virus–positive patients. **Only the premixed version of Avonex is applicable in the United
Kingdom. ***Cladribine was included with and without having still some uncertainty about its long-term side effects.
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Figure 2 Two warm-up and 1 regular discrete choice experiment question.
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evaluated based on a visual inspection of the chains and
the diagnostics as implemented in the OpenBUGS soft-
ware. The model codes with the full specification of the
priors are included in Supplementary Appendix D, with
detailed estimation results for the separate samples
included in Supplementary Appendix E.
Obtaining the full set of preference estimates was not
a goal in itself. Instead, conforming with DCE applica-
tions in the marketing literature,34,35 our goal was to
accurately summarize patient preferences for currently
existing and new DMTs. This was performed using 3
additional analyses. In the first, the individual-level pre-
ference estimates as obtained from the MIXL models
were used to calculate individual-level McFadden R2 sta-
tistics. Whereas a value of zero denotes random choice
behavior, McFadden36 suggested that R2 values between
0.2 and 0.4 represent an excellent model fit, constituting
the 3-level classification of 0.0–0.1, 0.1–0.2, and .0.2 to
denote poor, moderate, and excellent model fits, respec-
tively. Hence, the first analysis was used to confirm the
goodness-of-fit of the MIXL models and provide quanti-
tative credibility of the DCE results, in addition to the
qualitative information obtained from the think-aloud
interviews and survey satisfaction and cognitive debrief-
ing questions.
In the second analysis, the individual-level preference
estimates as obtained from the MIXL models were used
to estimate individual-level choice probabilities for all
DMTs in the competitive landscape. These were subse-
quently aggregated, separately by country and patient
characteristics, to obtain the percentage preference share
for each of the included DMTs. This approach has the
advantage of including all heterogeneity in patient prefer-
ences while simultaneously implying that much of the
uncertainty in the individual-level estimates cancels out
in the population preference shares.35 The required calcu-
lations were performed in MATLAB and were based on
the MCMC draws of the individual-level preference para-
meters. Accordingly, for all of the included scenarios,
Bayesian 95% credible intervals of the aggregate prefer-
ence shares could be reported that took the full uncer-
tainty of the underlying individual-level preferences into
account. The different scenarios that were included cap-
tured the impact of a significantly higher risk of progres-
sive multifocal leukoencephalopathy (PML) for MS
patients who are John Cunningham virus (JCV) positive,
the impact of the recent introduction of cladribine tablets
on patients’ DMT preferences, the impact of cladribine
tablets potentially still having some uncertainty about the
long-term side effects, the impact of patients’ experience
with MS (based on the number of years since MS
diagnosis), and patients’ experience with DMT modes of
administration based on their current and previous DMT
use.
In the third analysis, a principal component analysis
(PCA) was used to summarize the individual-level prefer-
ence structure of all participating respondents from the
United Kingdom and Germany combined. This follow-
up analysis was performed using STATA15 using an
orthogonal rotation to improve the interpretation of the
results.37 The PCA provided a concise description of the
patient choice process using a limited set of underlying
factors that were selected to jointly describe 99% of the
variation in patient preferences. As such, the PCA sum-
marizes the patient preferences as captured by the set of
48 parameters in the overarching DCE into a smaller
number of dimensions that are easier to interpret and
more relevant for clinical practice.
Role of the Funding Source
This study was sponsored by EMD Serono under con-
tractual freedom to publish the results irrespective of the
outcome of the study. The sponsor was kept apprised on
the progress and able to provide valuable comments on
the conduct of the study, while the Erasmus research team
had complete contractual freedom to make independent
decisions to uphold the scientific quality and integrity of
the study. In addition, the funding agreement included a
publication clause that guaranteed the Erasmus team to
publish the outcomes of the study irrespective of the spon-
sor’s approval.
In the exploratory interviews, participating physicians
and patients were not informed about the identity of the
study’s sponsor, making sure that all DMT profiles
would be presented and assessed in an equal and
unbiased manner. In the confirmatory interviews, physi-
cians were informed about the study’s sponsor and asked
to confirm that all DMTs were fairly and accurately
described.
Results
In total, 1770 UK and 648 German respondents con-
firmed to have been diagnosed with MS and agreed with
the informed consent. With many respondents excluded
because of the study’s RRMS inclusion criteria and with
several respondents dropping out during the survey
administration, this resulted in 799 and 363 completes
for the UK and German samples, respectively (see
Figure 3), with mean completion times of 33 and 39 min,
respectively. The UK and German sample were
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approximately equally divided in terms of educational
attainment but had a different pattern of current and
previous medication usage (Table 1). In Germany, parti-
cipating patients were more frequently using injections
(31%) than in the United Kingdom (24%) and less fre-
quently using oral medications (38% v. 48%). A similar
pattern was observed with respect to previously used
DMTs.
Overall, respondents were highly satisfied with the sur-
vey, could easily identify the differences between the treat-
ment options, and did not indicate that the number of
choice tasks was too large (Table 2). Thirty-seven respon-
dents (4.7%) in the United Kingdom and 22 respondents
(6.1%) in the German sample had individual-level R2
statistics smaller than 0.1. Vice versa, 652 respondents
(82%) and 290 respondents (80%) had R2 statistics
larger than 0.2, which was indicative of a good or even
excellent model fit. Excluding respondents with an R2
smaller than 0.1 had a negligible impact on the
presented results; therefore, no respondents were
dropped from the sample.
Table 3 presents the aggregated DMT preferences by
country and patient background characteristics. The dif-
ference in aggregated percentage preference shares
between German and UK patients was small. Therefore,
percentage preferences of the combined sample of UK
and German respondents are reported. Starting with the
historic base-case scenario, approximately 49% of all
patients preferred infusions, 28% orals, 18% injections,
and 5% preferred no DMT. The most often preferred
DMT was natalizumab (33%), with alemtuzumab (14%)
and teriflunomide (13%) ranked second and third.
Mitoxantrone and beta-interferon injections were least
often preferred. The introduction of cladribine tablets
into the therapeutic landscape constituted our base-case
scenario, in which cladribine tablets were included with-
out uncertainty about their long-term safety profile.
Here, natalizumab (26%) remained the most often
1770 respondents in the UK sample 
confirmed to be MS diagnosed and 
agreed with the informed consent
648 respondents  in the German sample 
confirmed to be MS diagnosed and 
agreed with the informed consent
22 respondents (1%) were flagged by 
the survey sample provider to be 
fraudulently included
614 MS patients (35%) did not meet 
the RRMS inclusion criteria
118 respondents (7%) used a computer 
with a foreign IP address
1013 eligible MS patients started 
with the survey questions
63 respondents (6%) dropped out 
before  starting with the DCE
90 respondents (9%) dropped out 
during the remainder of the study
61 respondents (6%) dropped out during 
the initial warmup questions
799 UK completes (86%)
14 respondents (2%) were flagged by 
the survey sample provider to be 
fraudulently included
227 MS patients (35%) did not meet 
the RRMS inclusion criteria
0 respondents (0%) used a computer with 
a foreign IP address
407 eligible MS patients started 
with the survey questions
9 respondents (2%) dropped out before  
starting with the DCE
21 respondents (5%) dropped out 
during the remainder of the study
12 respondents (3%) dropped out during 
the initial warmup questions
363 German completes (89%)
2 respondents (0%) were included both 
via NTD and SSI. (Their online 
responses were discarded.)
Figure 3 Flow diagram detailing the number of UK (left) and German (right) completes.
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preferred DMT, with cladribine tablets (with a prefer-
ence share of 22%) in second place. The introduction of
cladribine tablets had little impact on the preference
shares of injections (i.e., –10% on glatiramer acetate and
no impact on the beta-interferons), suggesting that cla-
dribine tablets and injections are relevant to different
patient segments and not in direct competition. In the
first sensitivity analysis, in which there was still some
uncertainty about the long-term side effects of cladribine,
cladribine tablets were considered less attractive and
received a much lower preferences share (i.e., –27%). In
the second sensitivity analysis, the increased risk of death
due to PML made natalizumab considerably less attrac-
tive, resulting in –85% preference share and with substi-
tution mainly occurring toward cladribine tablets (i.e.,
+36%), alemtuzumab (i.e., +40%), and fingolimod
(i.e., +43%). The third sensitivity analysis shows that
patients who were diagnosed longer ago are less likely to
prefer injections (13% v. 20% preference share) and
more likely to prefer more effective and less frequently
administered orals and infusions (i.e., alemtuzumab
and cladribine tablets). The fourth and final sensitivity
analysis indicates that experience with DMTs also mat-
ters. Compared with patients who have never used a
particular type of DMT, patients who have experience
with injections are more likely to prefer injections
(20% v. 9% preference share), patients who have expe-
rience with oral DMTs are more likely to prefer oral
DMTs (51% v. 27% preference share), and patients
who have experience with infusions are particularly
more likely to prefer infusions (57% v. 29% preference
share).
Table 1 Descriptive Statistics of the Patient Samples
United Kingdom Germany
Variable Obs Mean SD Min Max Obs Mean SD Min Max
Female 799 0.79 0 1 363 0.74 0 1
Age 799 42.6 10.0 18 79 363 42.0 10.8 18 71
Education (low)a 799 0.32 0 1 211 0.33 0 1
Education (medium)a 799 0.33 0 1 211 0.38 0 1
Education (high)a 799 0.35 0 1 211 0.29 0 1
Year of diagnosis 670 2009 6.47 1977 2016 348 2006 7.2 1977 2016
Currently uses injections 799 0.24 0 1 363 0.31 0 1
Currently uses pills 799 0.48 0 1 363 0.38 0 1
Currently uses infusions 799 0.14 0 1 363 0.16 0 1
Currently uses no MS medication 799 0.14 0 1 363 0.15 0 1
Previously used injections 799 0.57 0 1 363 0.78 0 1
Previously used pills 799 0.40 0 1 363 0.30 0 1
Previously used infusions 799 0.22 0 1 363 0.24 0 1
Previously used no MS medication 799 0.23 0 1 363 0.07 0 1
aLow education refers to International Standard Classification of Education (2011) levels 0–2, medium education to levels 3–4, and high
education to levels 5–8. MS, multiple sclerosis; Obs, observations.
Table 2 Summary of Survey Evaluation Questionsa
United Kingdom Germany
Question Obs Mode Mean SD Obs Mode Mean SD
The choice tasks were clear 799 7 6.0 1.3 363 7 5.7 1.5
The choice tasks were interesting 799 7 5.8 1.3 363 7 5.6 1.6
I could easily identify the differences between the treatment options 799 7 6.0 1.4 363 7 5.7 1.6
I could easily choose between the treatment options 799 7 5.5 1.6 363 7 5.5 1.6
I could easily have answered more choice tasks 799 4 5.0 1.6 363 7 4.7 2.2
There were too many choice tasks 799 4 3.7 1.8 363 1 3.6 2.0
The survey’s topic was interesting 799 7 6.0 1.4 363 7 6.0 1.5
aRespondents were asked to evaluate the statements on a 7-point Likert-type scale, ranging from 1 (I completely disagree) to 7 (I completely
agree). Obs, observations.
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Table 4 summarizes the results of the PCA analysis.
As shown, patient preferences could be summarized in 8
underlying factors that together explain 99% of the
between-respondent variation in DMT preferences.
Based on the component loadings (see Supplementary
Appendix E Table 4E), which describe how each under-
lying factor correlates with the estimated patient prefer-
ences in the DCE, the first 3 factors described the
patients’ desire for highly effective DMTs and patients’
aversion for the associated side effects. Whereas prefer-
ences for many side effects were bundled into a single
factor, preferences for the risk of PML were loaded on a
separate factor, suggesting that risk of PML is an inde-
pendent consideration. The fourth factor captured
patient preferences for the lowest frequency of adminis-
tration, and the next 3 factors were interpreted to
describe the tradeoff between the slightly less effective
oral and injectable DMTs. Apart from the general pre-
ference that patients may have for injections versus oral
DMTs, this tradeoff was predominantly based on
patients’ relative preferences for the risk of gastrointest-
inal upset, flulike symptoms, skin problems, and lipoa-
trophy. The eighth and final factor described patient
preferences for pregnancy-related considerations. In
the questionnaire, 77% of the respondents indicated
pregnancy-related considerations to be unimportant, but
for the remaining 23%, these considerations could be
decisive in their choice of DMT.
Table 4 Patient Preference Driversa
1 Preferences for the most effective DMTs, irrespective of mode of administration
2 Preferences for the more effective DMT side effects (i.e., gastrointestinal problems, flushes, and increased risk of serious
infections, heart problems, thyroid disorder, kidney problems, and/or blood clothing disorder/immune thrombocytopenia)
3 Preferences for risk of dying from progressive multifocal leukoencephalopathy
4 Preferences for lowest frequency of administration
5 Preferences for injections and oral DMTs v. infusions
6 Preferences for injection-related side effects (e.g., flulike symptoms, lipoatrophy)
7 Preferences for intramuscular injections with fewer skin problems
8 Preferences for pregnancy-related considerations
aDMT, disease-modifying treatment. Supplementary Appendix E contains the full table with component loadings for each of the attributes and
levels (i.e., 48 parameters) on the principal components.
Box 1
What is already known on this topic?
 The therapeutic landscape for relapsing-remitting multiple sclerosis (RRMS) is rapidly expanding and currently comprises 13
disease-modifying treatment options (DMTs).
 Because no single optimal treatment exists, therapy should ideally be tailored to patients’ preferences as well as disease
progress and severity.
 Existing patient preference studies (see Supplementary Appendix A and a recent review by Webb et al.38) have been
informative about the general stance of patients on the risk/benefit tradeoffs but have neither included nor analyzed
preferences for actual DMTs. Accordingly, previous studies provided limited guidance to clinicians aiming to align treatment
selections with patients’ preferences.
What this study adds:
 This study is the first to provide insight into patients’ considerations when choosing between entire RRMS DMT profiles
and the first to present aggregate patient preference shares for all included DMTs in a competitive landscape of treatment
options. In the presented RRMS application, mitoxantrone and beta-interferon injections were seldom preferred, whereas the
vast majority of patients preferred either one of the oral DMTs (42%) or natalizumab/alemtuzumab infusions (36%).
 Eight principle components were identified that together explain 99% of the variation in patients’ preferences for RRMS
DMTs. These allow for a structured discussion of the most important differences between DMTs, precisely along the
dimensions on which MS patients base their decision.
 Finally, new treatment options will continue to be introduced into the competitive landscape and older treatment options will
continue to become obsolete. The presented DCE methods are ideally suited to capture these effects and, describe the
substitution patterns. This is relevant for various disease areas other than MS and useful for future regulatory decisions.
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Discussion
Patient preferences in Germany and the United Kingdom
for RRMS DMTs were very similar despite substantial
differences in actual DMT usage. Patients in both coun-
tries predominantly preferred oral DMTs (41%) and infu-
sions (38%). Beta-interferon injections and mitoxantrone
had the smallest preference share among RRMS patients.
Natalizumab was the most often preferred DMT, and cla-
dribine tablets were the most often preferred oral DMT.
Given this is the first study to calculate preference shares
for the competitive landscape of RRMS DMTs, it is not
possible to compare our results with previous findings,
except for those pertaining to the relative attractiveness of
oral and infusions over injections. With respect to the lat-
ter, our results confirm that patients generally prefer infu-
sions and oral DMTs over injections.
Another key finding of the study is that patient
choices between different DMTs can be summarized
using 8 underlying factors. This finding is relevant for
clinical practice, where physicians often select a ‘‘candi-
date set’’ of DMTs (2 or 3 options) that might be rele-
vant for the patient and then discuss the pros and cons
of each during the patient-physician consultation. The
identification of these 8 factors allows for a structured
discussion of important differences of the selected DMTs
along the dimensions that MS patients base their deci-
sion upon. These findings also imply that less emphasis
can be placed on aspects that are not particularly impor-
tant for patients choosing between DMTs, such as the
frequency of required monitoring for serious side effects.
Clearly, actual DMT usage reflects not only patient
preferences for DMT characteristics but also physician
preferences, prescription guidelines, reimbursement poli-
cies, and marketing efforts to increase brand awareness.
Consequently, the presented preference shares can and
should not be interpreted as predicted market shares.
Similarly, actual market shares are not particularly infor-
mative about patient preferences, which is why a DCE is
ideally suited to measuring and summarizing patient pre-
ferences for DMTs.
In terms of the strengths of this study, it is worth
emphasizing that the participating patients were very sat-
isfied with the survey, could easily identify the differences
between the treatment options, and did not indicate that
the number of choice tasks was too large. The MS nurses
and interviewers who conducted the think-aloud survey
evaluations considered the level of task complexity to be
manageable for their patients. Furthermore, the quanti-
tative assessment based on the individual-level R2 esti-
mates confirmed that more than 80% of the respondents
had good or excellent model fit. In addition, the results
have good face validity, and the included scenarios pro-
vided logically consistent results; the uncertainty about
long-term side effects, a higher risk of PML for JCV-pos-
itive patients, and patients’ experience with MS and
modes of administration were strongly correlated with
patient preferences for DMTs.
In terms of lessons learned for future studies, the fea-
sibility of the presented methods crucially relied on the
ability to keep the level of task complexity manageable
for all respondents while simultaneously maximizing sta-
tistical efficiency. On one hand, the carefully constructed
warm-up tasks, the adaptive visual layout that omitted
irrelevant side effects and highlighted the level overlap,
the maximum number of side effects per DMT and mini-
mum amount of attribute-level overlap were all essential
to reducing the level of task complexity. On the other
hand, a Bayesian efficient heterogeneous DCE design
algorithm that adhered to the specified design con-
straints, made use of informative priors, and simultane-
ously optimized the choice tasks for the various DCE
sections had to be used to achieve adequate statistical
power. Indeed, given the limited sample size and the
imposed design constraints, a more traditional zero-prior
DCE design would not have sufficed.
An important limitation of this study is the fact that
the most recently introduced RRMS DMT (i.e., ocrelizu-
mab) was not included in the competitive landscape
because the required information was not available when
the study was designed. In a future extension of this study,
it would be interesting to include ocrelizumab and investi-
gate the impact on the presented results. Of course, new
treatment options will continue to be added to the compet-
itive landscape, and older DMTs with less favorable risk-
benefit tradeoffs will continue to diminish in relevance.
The presented methods are ideally suited to capture these
effects, describe the substitution effects, and show how
patient preferences adapt to future competitive landscapes.
As with any preference study, the carefully con-
structed DCE profiles are an abstraction from reality
and inherently based on a limited number of levels and
incidence descriptions. This is a limitation in any DCE
but particularly one in a study aimed at summarizing
patient preferences for complex DMTs. Accordingly,
maximum effort has been placed on representing all
DMTs in the most realistic and balanced way possible
and to allow patients to make realistic tradeoffs between
a large number of important aspects of RRMS DMTs.
Compared to previous preference studies, the current
study was able to include considerably more detailed
profiles. The presented analyses consequently supplement
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previous research not merely by showing which general
aspects of DMTs are important to patients but also by
showing how RRMS patients make choices between
actual DMTs and how this translates into preference
shares of various DMTs that are either currently avail-
able or will be introduced in the near future. The latter
has methodological relevance beyond the current applica-
tion and will be particularly useful for regulatory deci-
sions about future DMT introductions.
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